BioStock: PHI aims for US listing

July 11, 2024
Language flag

Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.

Read the full interview with Patrik Eschricht on biostock.se.

We are very happy about the possibility of dual-listing on the OTCQB, which would be another significant step in PHI’s growth journey as a global company. This dual listing would make it more accessible for international investors to invest in PHI, positively increasing liquidity, boosting shareholder value, and supporting our ongoing growth.

Further reading

BioStock-PHI-CEO-reflects-on-the-company-momentum

BioStock: PHI’s CEO reflects on the Company’s momentum

BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.
Biostock-Altium-fuels-PHIs-forward-drive

BioStock: Altium fuels PHI’s forward drive

BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore the current pivotal developments and their impact on PHI’s trajectory.
Businesspeople brainstorming together with sticky notes in an of

BioStock: PHI links up with two regenerative medicine networks

BioStock contacted CEO Patrik Eschricht to learn more about the company’s future strategies in regenerative medicine and the pivot toward the clinical market.
BioStock: PHI charts a bold course to impact regenerative medicine

BioStock: PHI charts a bold course to impact regenerative medicine

BioStock contacted CEO Patrik Eschricht to delve into the year-end report’s highlights and shed light on the company’s vision and initiatives.
1…45678…10

Latest News

Phase Holographic Imaging Announces Next Generation HoloMonitor

Phase Holographic Imaging (PHI) is pleased to announce that the next generation of PHI’s live cell imaging system enters its final development stage. The new model is currently undergoing pre-production testing both internally and externally at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine.
Phase Holographic Imaging logotype

Phase Holographic Imaging Announces Management Changes

Recent technical progress has led the Board of Directors of Phase Holographic Imaging (PHI) to decide to focus resources on the company’s clinical product development program. In relation to this, the Board of Directors has, in discussion with CEO Anders Månsson, decided to initiate the search for a new CEO to lead the ambitious development that lies ahead.

PHI announces last day of trading in BTA

See All News